The Effect of Oral Pre-Exposure Prophylaxis on the Progression of HIV-1 Seroconversion

Authors: Deborah DONNELL PhD\textsuperscript{1,2}, Eric RAMOS MD, MSc\textsuperscript{2}, Connie CELUM MD MPH\textsuperscript{3,4,5}, Jared BAETEN, MD, PhD\textsuperscript{3,4,5}, Joan DRAGAVON, MLS\textsuperscript{2}, Jordan TAPPERO, MD, MPH\textsuperscript{7}, Jairam R. LINGAPPA MD, PhD\textsuperscript{3,5,6}, Allan RONALD MD\textsuperscript{8}, Kenneth FIFE MD PhD\textsuperscript{9} and Robert W COOMBS, MD, PhD, FRCPC\textsuperscript{2}, for the Partners PrEP Study Team*

Affiliations

\textsuperscript{1}Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle WA, USA

\textsuperscript{2}Department of Laboratory Medicine, University of Washington, Seattle WA, USA

\textsuperscript{3}Department of Global Health, University of Washington, Seattle WA, USA

\textsuperscript{4}Department of Epidemiology, University of Washington, Seattle WA, USA

\textsuperscript{5}Department of Medicine, University of Washington, Seattle WA, USA

\textsuperscript{6}Department of Pediatrics, University of Washington, Seattle WA, USA

\textsuperscript{7}Division of Global Health Protection, Center for Global Health, CDC, Atlanta, GA, USA

\textsuperscript{8}Departments of Medical Microbiology and Internal Medicine, University of Manitoba, Manitoba, Canada

\textsuperscript{9}Department of Microbiology and immunology, Indiana University, IN, USA

* Members of the Partners PrEP Study Team noted after the Acknowledgements
Running Title: PrEP and progression of acute HIV

Disclaimers

The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Correspondence to:

Deborah Donnell
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center
1100 Fairview Ave N, Seattle, WA 98109
Email: deborah@fredhutch.org
Tel: 1-206-667-5661
Fax: 1-206-667-4378

Conflict of Interest and sources of funding:

None of the authors has declared a conflict of interest.

The Partners PrEP Study was funded through a research grant from the Bill & Melinda Gates Foundation (grant ID #47674). Central laboratory support for HIV-1 testing was provided in part through the University of Washington Center for AIDS Research, funded by the US National Institutes of Health under award number P30 AI027757. Gilead Sciences donated the study medication but had no role in data collection or analysis.

Data presented previously at R4P Conference, Chicago, October 2016. Abstract OA03.01
ABSTRACT

Objective: To investigate whether oral pre-exposure prophylaxis (PrEP) alters timing and patterns of seroconversion when PrEP use continues after HIV-1 infection.

Design: Retrospective testing of the timing of Fiebig stage HIV-1 seroconversion in the Partners PrEP Study, a randomized placebo-controlled clinical trial of PrEP conducted in Kenya and Uganda.

Methods: Specimens from 138 seroconverters were collected every 3 months and when HIV-1 infection was suspected based on monthly rapid HIV-1 tests. Progression of seroconversion was compared between randomized groups (PrEP versus placebo) and per-protocol groups (placebo versus PrEP participants with detectable tenofovir during the seroconversion period) using laboratory assessment of Fiebig stage. Delay in site-detection of seroconversion and association with PrEP drug-regimen resistant virus were assessed using logistic regression. Analysis of time to each Fiebig stage used maximum likelihood estimation with a parametric model to accommodate the varying lengths of HIV-infection intervals.

Results: There was a significant increase in delayed site detection of infection associated with PrEP (OR=3.49, p=0.044). Delay in detection was not associated with increased risk of resistance in the PrEP arm (OR=0.93, p=0.95). Estimated time to each Fiebig stage was elongated in seroconverters with evidence of ongoing PrEP use, significantly for only Stage 5 (28 days versus 17 days, p=0.05). Adjusted for Fiebig stage, viral RNA was ~2/3 log lower in those assigned to PrEP compared to placebo; no differences were found in Architect S/CO at any stage.
**Conclusions:** Ongoing PrEP use in seroconverters may delay detection of infection and elongate seroconversion, although the delay does not increase risk of resistance.

**Keywords:** pre-exposure prophylaxis, early HIV-1 seroconversion, HIV-1 RNA, HIV-1 testing, Fiebig stages
INTRODUCTION

Multiple randomized clinical trials have shown that with good adherence, pre-exposure prophylaxis (PrEP), substantially reduces risk of HIV-1 acquisition\(^1-^6\). This prevention strategy requires frequent high-quality HIV-1 testing among PrEP users to detect acute/early HIV-1 infection and minimize risk of resistance. Non-adherence to PrEP provides little HIV-1 protection but at the same time little risk of resistance if the patient is infected\(^7\), whereas high adherence to PrEP blocks most transmissions\(^8\). For those who acquire HIV-1 in spite of PrEP – whether from sporadic adherence, or potentially a breakthrough with high adherence – it is unknown if PrEP use modifies the progression of seroconversion or the natural evolution of HIV-1 biomarkers.

In 2003, Fiebig\(^9\) developed a classification schema of primary HIV-1 infection using sequential assay reactivity to identify six distinct laboratory stages of acute/early HIV-1 infection over approximately a three-month period following HIV-1 acquisition. The Fiebig stages document the progression of infection from an initial "eclipse phase" in local mucosal tissue, through dissemination to regional lymph nodes to systemic spread accompanied by high levels of HIV-1 replication in the blood\(^1^0,^1^1\).

The primate model of PrEP has shown reduced peak virus load and suppressed maturation of antibody avidity with PrEP break-through of SHIV\(_{SF162P3}\) infection but little impact on the timing of seroconversion and neutralizing or binding antibody levels\(^1^2\). If PrEP is used during all or part of acute HIV-1 infection, when antibody response develops, it is biologically plausible that these biomarkers of acute HIV-1 infection, HIV-1 RNA and p24 antigen and antibodies against HIV-1 will be delayed, attenuated, or perhaps even skipped.

Within a placebo-controlled trial of PrEP, we assessed whether PrEP use affected the
detection of infection, timing of Fiebig stages, or virological and immunological response to HIV-1 infection.

METHODS

Study population

Participants in the double-blinded Partners PrEP Study were enrolled in Kenya and Uganda, and randomized 1:1:1 to receive daily emtricitabine/tenofovir (FTC/TDF), TDF or placebo. Participants were seen monthly for HIV-1 testing and provision of a one-month supply of study medication [13]. Those with reactive or discordant rapid tests were considered possible seroconverters, and confirmed by third generation EIA at the local laboratory. Study drug was temporarily withheld for any HIV-reactive test, and permanently discontinued once seroconversion was confirmed. Plasma and serum samples were stored at months one, three and each subsequent quarterly visit, at any visit with a reactive HIV-1 test, and for seroconverters, at visits within a month and then quarterly thereafter. HIV-1 infections were confirmed centrally from stored samples.

Participants (N = 4,747) were enrolled between July 2008 and November 2010. In July 2011, the independent data monitoring committee recommended that use of placebo be discontinued because the PrEP intervention had demonstrated overwhelming efficacy. The study continued participants in the active arms and placebo-arm participants were unblinded and offered re-randomization to the continuing active arms. Thus, there were two study periods: a primary randomized period with participants assigned 1:1:1 to placebo, TDF and FTC/TDF, and the post-DMC placebo unblinding period in which unblinded placebo participants were re-randomized 1:1 to TDF and FTC/TDF [8, 13]. All participants
provided written informed consent in English or their local language, including re-consent for re-randomization (ClinicalTrials.gov number NCT00557245). The study protocol was approved by the University of Washington Human Subjects Review Committee and ethics review committees at each study site.

**Laboratory methods**

Sites used the Determine (Alere) rapid test kit run in parallel with any of the Unigold (Trinity Biotech), Bioline (Standard Diagnostics) or STAT-PAK (Chembio Diagnostic Systems) whole blood rapid tests; reactive rapid tests were confirmed with either a 3rd or 4th generation confirmatory EIA serum test\[^{14, 15}\]. Additional testing, performed at the Department of Laboratory Medicine, University of Washington (Clinical Laboratory Improvement Amendment (CLIA) certified and College of American Pathologists (CAP) accredited) established the last HIV-1 non-reactive visits and assessed Fiebig stage using plasma. Laboratory testing included: HIV-1 RNA detection using the Abbott m2000rt Real Time HIV-1 RNA (Abbott Molecular) with limit of detection of 40 copies/mL; HIV-1 p24 antigen/HIV-1/2 antibody detection using the ARCHITECT HIV-1/2 Ag/Ab Combo CMI assay (Abbott Diagnostics) and Bio-Rad HIV-1/2 Ag/Ab Combo EI assay; IgM/IgG antibody detection, confirmation and discrimination using the Multispot HIV-1/HIV-2 rapid test (Bio-Rad Laboratories); and Western blot (Genetic Systems HIV-1 WB assay (Bio-Rad Laboratories). A Multispot rapid test was considered positive if both HIV-1 dots developed, per the manufacturer; a single HIV-1 spot was considered indeterminate. The Western blot was considered HIV-1 positive if any two of the p24, gp41 or gp120/160 were reactive: any other blot reactivity was considered indeterminate.
Plasma tenofovir concentrations were determined in selected archived plasma samples by previously described ultra-performance liquid chromatography-mass spectrometry assay methods\(^{[16, 17]}\). Calibration standards ranged from 0.31–1280 ng/ml. Drug susceptibility genotype was performed and reported elsewhere for all the PrEP study HIV-1 infections including the discordant HIV-1–infected partners\(^{[7, 8]}\).

**Outcomes**

To investigate the effect of PrEP on HIV-1 during acute/early infection we assessed: 1) time to site detection of HIV-1 infection, 2) time to each Fiebig stage, 3) HIV-1 viral RNA and 4) overall antibody response (as measured by Architect signal to cut-off (S/CO) ratio). In addition, we assessed whether occurrence of resistant virus was associated with delay in site detection of infection.

Time to site detection of HIV-1 infection was from time of sample with first evidence of infection to time of site-detected seroconversion. Analysis of time to Fiebig stage was based on all samples available during the “seroconversion period”, defined as from the last HIV-1 uninfected visit to when Fiebig stage six was first reached. While HIV-1 testing was monthly, samples were stored every 12 weeks. Delay in site detection of seroconversion was defined as >100 days between first HIV-1 infected sample and site detection of infection, to allow for the maximum interval between stored samples. Similarly, since the probability of detecting early Fiebig stages is higher with shorter sampling intervals, the length of time between samples was explicitly incorporated into the analysis estimating Fiebig stage duration (see supplementary Appendix 1, http://links.lww.com/QAD/B132).

Both analyses exclude seroconverters who missed study visits and did not receive HIV-1
testing at the site for >100 days, as they do not contribute information about early progression of seroconversion.

Treatment arm was defined as PrEP (TDF/FTC or TDF) if randomized to PrEP at any time during the seroconversion period (defined above). If site rapid tests were non-reactive, participants were randomized and started on PrEP. Seroconverters whose infection was not detected prior to starting PrEP were included in the PrEP group. Analyses assessed exposure to PrEP both “as-randomized” and “as-treated”, with the latter defined as detectable tenofovir concentrations in plasma in any sample during the seroconversion period. Detectable tenofovir concentrations at the last HIV-1 uninfected visit were excluded if the participant subsequently missed study visits for more than 100 days.

The testing algorithm used to define the last uninfected visit and Fiebig stage definitions are shown in Table S1. We note a modification of the original Fiebig staging in the definition of Stage 3, substituting the Multispot rapid test for Fiebig’s older “sensitive” EIA; a positive Multispot has been characterized as occurring 7 days prior to a positive WB[18]. Because of the potential for PrEP to suppress HIV-1 RNA level in plasma, detectable HIV-1 RNA was not required for Fiebig stages two to six.

**Statistical Methods**

Delay in detection associated with PrEP was assessed using logistic regression, as was occurrence of drug resistant virus and delayed detection in the PrEP arm.

A parametric model was used to test whether cumulative time to reach each Fiebig stage was attenuated by PrEP use. Each participant’s sequence of available data consisted of time of last HIV-1 uninfected sample ($t_2 = 0$); time and stage of first HIV-infected sample ($t_1$),
and a series of subsequent times and stage of infection up to the first Fiebig stage 6 sample \( (\tau_6) \). The “infection interval” was defined as the time between the last HIV-1 uninfected and first HIV-1 infected sample \((0, \tau_{\text{max}}] \). Time to each Fiebig stage, \( \tau_k \), after (unobserved) time of infection was assumed to follow an Exponential waiting time distribution with mean \( 1/\lambda_k \). The assumption of an exponential waiting time was judged appropriate as the estimated durations in the placebo arm closely match those originally reported by Fiebig\(^9\). The time of infection was assumed to be Uniformly distributed in the infection interval \((0, \tau_{\text{max}}]\). The parametric survival distribution and contributions to the likelihood for time to Stage k under these assumptions are given in Appendix 1 (supplementary material, http://links.lww.com/QAD/B132).

To test the hypothesis that the time to reach Fiebig stage k was longer for persons on PrEP than placebo, we modelled \( \lambda_k^P = \alpha_k \lambda_k^0 \), where \( \lambda_k^P \) is the event rate for PrEP arm, \( \lambda_k^0 \) the event rate for placebo arm, and \( \alpha_k \) the relative increase in time to Stage k attributed to PrEP use. Note that time to Stage 1 was inestimable, since the earliest possible detection of infection is synonymous with Stage 1. \( \alpha_1 \) was estimated using maximum likelihood; 95% CI were computed using Fisher Information. P-values were computed via bootstrap estimation, using permutations of the assignment of PrEP versus placebo.

Comparison of viral load (\( \log_{10} \) RNA copies/mL) and Architect S/CO between groups used Generalized Estimating Equation (GEE) models adjusted for Fiebig stage.

**RESULTS**

There were a total of 138 HIV-1 seroconverters: 67 were assigned to PrEP during the seroconversion period (40 TDF, 27 FTC/TDF), and 71 received placebo. Fifteen were
HIV-1 infected (HIV-1 RNA detected) but seronegative at initial randomization, 111 became infected on study, nine infections occurred during an off-study drug period and three were infected at placebo re-randomization. About half were men (46%), the median age was 30, and median viral load of their HIV-1 infected partners was >20,000 copies per/mL (Table 1). Among the 67 randomized to PrEP, 64 were assessed for tenofovir in plasma during the seroconversion period and 31 (48%) had detectable tenofovir during that period, of whom 15 had tenofovir concentrations >40 ng/mL, consistent with daily dosing [19, 20].

_Detection of HIV-1 seroconversion_

Assessment of delay in detection of infection included 129 seroconverters; nine with no site HIV-1 test in the 100 days prior to detection of seroconversion because of missed study visits were excluded (Table 1; Figure 1). For 57 (44%) the first infected visit (identified by subsequent central lab testing) coincided with site detection of seroconversion; for a further 58 (45%), site diagnosis of seroconversion occurred within 100 days of the first infected visit. Of the 14 for whom infection was not detected by monthly site HIV-1 testing for more than 100 days, 4 were assigned to placebo and 10 to PrEP, 9 of these were in the as-treated group. The odds ratio (OR) for a delay >100 days in detection of seroconversion for PrEP vs. placebo was 3.49 (95% CI 1.03-11.8, p = 0.044); for PrEP as-treated versus placebo, OR = 7.18, (95% CI 2.00-25.7, p = 0.002). As previously reported [7, 13], 6 PrEP seroconverters had virus with mutations associated with resistance to TDF or FTC/TDF; for 5/6 where the partner was the source of the virus, resistance appears to have been selected by PrEP. All of these were in the as-treated group, but there was no association in the PrEP
arm between having a resistant mutation and delay in site detection of infection (OR = 0.925, p = 0.95; Figure 1).

Progression and time to reach Fiebig stages

All 138 seroconverters were observed through Fiebig Stage 5 or 6 (i.e., final sample was Western blot positive), with none initiating antiretroviral therapy for treatment during the seroconversion period. A total of 88 (64%) seroconverters had samples from more than one Fiebig stage; the remaining 50 (36%) were Stage 6 at their first HIV-infected visit. Of the 138 seroconverters, 113 were included in the analysis of time to Fiebig stage: 16 were excluded because they had no HIV-1 uninfected sample and 9 because they had >100 days with no site HIV-1 test prior to detection of seroconversion. Figure 2 shows the infection interval and the stages detected during seroconversion period by time since beginning of infection interval. Amongst these 113, 74 (65%) seroconverters had samples from more than one Fiebig stage; and 39 (35%) were Stage 6 at their first HIV-infected visit.

Randomization to PrEP was not associated with a statistically significant increase in time to Fiebig stage, for any stage (Table 2). However, comparing as-treated PrEP to placebo groups, a statistically significant relative increase in time to reach stage 5 was observed ($\theta_5 = 0.599$, $p = 0.05$), corresponding to an increase in mean days to full Western Blot from 49 days amongst placebo to 80 days for seroconverters taking PrEP. There was a consistent pattern of relative increase in time to reach each Fiebig stage in PrEP compared to placebo at all stages in both as-randomized and as-treated comparisons, and consistently higher relative increases in as-treated compared to as-randomized comparisons against placebo.

Plasma viral load during seroconversion in PrEP versus placebo participants
Plasma HIV-1 RNA level, adjusted for Fiebig stage of sample, was \(-2/3 \log_{10}\) lower in those assigned to PrEP compared to placebo (\(-0.64 \log_{10}\) copies/mL 95%CI \(-0.94 \text{ to } -0.34;\) p< 0.001) and \(-3/4 \log\) lower in PrEP as-treated compared to placebo (\(-0.74 \log_{10} \text{ copies/mL 95%CI } -1.11 \text{ to } -0.36;\) p < 0.001). For samples in Stage 2-6 (Table 1), 4/134 (3%) on placebo and 13/121 (11%) on PrEP had undetectable viral load (OR = 3.9 95%CI 1.24-12.4; p = 0.02). To exclude an integrase target detection problem with the Abbott m2000 HIV-1 RNA test, these samples were also confirmed to be HIV-1 RNA negative using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test, v2.0, which targets HIV-1 LTR and gag.

No differences were found in Architect S/CO comparing PrEP to placebo in as-randomized or as-treated comparisons (Figure 3).

DISCUSSION

In this analysis of a randomized, placebo controlled trial of PrEP, we showed that PrEP delayed the time to detect seroconversion for those participants who continued to take PrEP during acute/early clade C HIV-1 infection. Nonetheless, the majority of HIV-1 infections were detected within 3 months, which corresponds to the currently recommended HIV-1 testing frequency for patients on PrEP. We also observed a consistent trend of increased time for Fiebig stage progression among the seroconverters with TDF-monitored evidence of continued PrEP exposure. A statistically significant delay occurred only for Fiebig stage 5, likely because it has the longest duration and thus was observed most frequently. While our analysis suggests PrEP may elongate seroconversion, the delay in detection was not associated with developing resistant virus, thus the clinical consequences on seroconversion appear unlikely to be significant.
Our findings are similar to those from a randomized trial of TDF PrEP among injection drug users, which also reported a substantial delay in detection of clade A/E HIV-1 seroconversion in the TDF arm using the OraQuick oral fluid test\cite{21}. A study among women in South Africa also observed a delay in antibody maturation following clade C HIV-seroconversion in women assigned to TFV gel\cite{12}. In primate studies, delay in seroconversion was not observed in PrEP breakthrough infections, although maturation of antibody avidity was delayed\cite{22}. We did not assess antibody maturation in our study.

Consistent with the primate studies\cite{22, 24}, we found that PrEP suppressed viral replication during seroconversion, a reassuring consequence of antiretroviral exposure during acute and early infection. Lower viral loads have not been observed in other PrEP trials\cite{2, 25, 26}, although this may be attributable to lower adherence to PrEP. In two recently reported cases of multidrug resistant breakthrough infections in which self-report and drug detection indicated high adherence to PrEP, viral load remained suppressed or low throughout seroconversion\cite{27, 28}.

Naturally occurring (i.e., placebo arm) suppression of viral load during acute/early infection was also observed, as was prolonged time to detect seroconversion, suggesting that there are also host determinants of the seroconversion process. To date, studies of acute and early HIV-1 seroconversion have used detection of viral RNA to define the earliest evidence of infection immediately following the eclipse stage\cite{29-31}, thus, naturally occurring suppression of RNA viral load during acute/early infection is not often observed, although it has been previously reported\cite{32, 33}. Elongation of time to develop detectable HIV-1
infection beyond 4 months could reflect either the performance of the HIV-1 rapid tests\cite{34-36} or a delay in development of HIV-1 antibody\cite{37, 38}.

Prolongation of time to full seroconversion could indicate alteration of the early immunological response to HIV-1 or delayed serologic progression in response to lower viral replication. The lack of difference in the Architect S/CO ratios indicated no evidence of differences in the overall antibody response to HIV-1 infection; thus a delay in progression to Fiebig stage 5 is most likely attributable to lower viral burden during seroconversion.

Resistance mutations to TDF or FTC have been rare in PrEP clinical trials: eight (18%) HIV-1 infections with mutations occurred among 44 individuals HIV-1–infected at enrollment (two on placebo and six on PrEP); among incident HIV-1 infections, drug-resistant infections have been detected in 1/254 on placebo and 5/164 on PrEP\cite{39}. Recently two cases of multi-drug resistant breakthrough infections have been reported in patients with consistent adherence to daily PrEP\cite{27, 28}. It is plausible that drug resistant mutations may be more likely to develop if PrEP significantly delays diagnosis of HIV-1 infection. In our study, although all resistance mutations occurred in those who continued PrEP after infection, mutations conferring resistance to FTC/TDF were not related to delayed detection. It seems likely that drug exposure was low when infection occurred, and ongoing selective pressure, because of either high or no adherence, was not sufficient for resistance to be common. Reassuringly, there is little indication that a delay in detection of infection increases the chance of resistance mutations.

At the time of this study, antibody-based rapid tests were in use as the standard for detection of new HIV-1 infections at participating sites. In just over half the cases, these
tests did not detect HIV-1 infection at the first HIV-1–infection visit, as these rapid tests are not highly sensitive during early infection. Similar findings of imperfect detection of early infection with rapid enzyme immune assays (EIA) tests have been reported in other PrEP studies[35, 36]. The more sensitive EIA and chemiluminescent microparticle immunoassay Ag/Ab tests now available, and recommended for use in patients on PrEP, would likely detect infections at the earlier Fiebig stages as we demonstrated. The higher frequency of visits with undetectable HIV-1 RNA during seroconversion among those assigned to PrEP suggests that use of viral RNA as a confirmatory or diagnostic test may not be adequate, and total nucleic tests for cell-associated HIV-1 RNA and DNA may be required to rule out HIV-1 infection in the presence of inconclusive HIV-1 diagnostic tests.

A significant limitation in our study of Fiebig stages is the 1-3 month gaps between stored samples needed for staging, compared to the 1-2 week durations for Fiebig stages 1-4. With the limited number of seroconverters on PrEP, we had limited power to detect changes in time to reach each stage. The strengths of the study are that in this cohort, with high retention and relatively high adherence to both visits and PrEP, samples were stored and available every three months for almost every seroconverter during seroconversion. Our testing strategy did not duplicate the earlier but elegant Fiebig staging schema because of the change in HIV-1 diagnostic platforms from second and third generation assays used by Fiebig to third and fourth generation assay platforms used in our study; as such, our staging approach for acute/early HIV-1 infection should be considered a modification to the original Fiebig staging. Nevertheless, the close similarity in stage duration between the original and modified schemas suggests that current-testing algorithms can be used to define a contemporary Fiebig staging schema for acute/early HIV-1 infection[40].
CONCLUSION
The 2015 WHO recommendation that PrEP be implemented as part of an effective prevention package for persons at substantial risk of HIV-1 infection is leading to increasing scale-up of PrEP. Delay in detection of HIV-1–infection as a result of PrEP use would be a concern if the recommended quarterly HIV testing missed diagnoses and inadvertently prolonged PrEP exposure after infection, thereby increasing risk of resistance mutations; our study is reassuring in not finding evidence of this risk. Our study suggests that delay in progression of seroconversion is likely a result of PrEP’s suppression of viral replication: as aligned with the goal of early treatment interventions, this may ultimately prove to be beneficial to the patient. Future study of delay or even aborted development of viral and antibody markers in HIV-1 seroconverters with continued PrEP exposure will be important in the US and other settings where much more frequent testing is now routine. We concur with the need to use highly sensitive rapid HIV-1 tests in patients using PrEP so that delays in developing full Western blot pattern (or equivalent) will not delay detection of HIV-1 infection. The potential benefit for TDF-containing oral PrEP to prevent HIV-1 acquisition remains high, and our analysis adds support to a risk-benefit ratio clearly in favor of continuing the effort to scale-up PrEP in populations with substantial HIV-1 risk.

ACKNOWLEDGMENTS
DD, CC and JB contributed to the design and execution of the study had full access to the data. DD conducted the statistical analyses and wrote the first draft of the manuscript. ER, JD and RB conducted the laboratory testing and contributed to the design of the study. JT,
JRL, AR and KF contributed to the design and execution of the study. All authors contributed to critical review and approved the final manuscript.

We are grateful to the couples who participated in this study for their motivation and the study team members for their unflagging dedication. We thank the members of the independent Data and Safety Monitoring Board for their wisdom and guidance throughout the trial. We also thank James Bremer PhD and Cheryl Jennings, NIH/NIAID/DAIDS Virology Quality Assurance Program, Rush Medical College, Chicago, IL for the confirmatory Roche TaqMan testing (HHSN272201200023C, HHSN266200500044C).

We also acknowledge the tireless efforts of the study team.

**Funding:**

The Partners PrEP Study was funded through a research grant from the Bill & Melinda Gates Foundation (grant ID #47674). Central laboratory support for HIV-1 testing was provided in part through the University of Washington Center for AIDS Research, funded by the US National Institutes of Health under award number P30 AI027757 and UM1-AI106701. Gilead Sciences donated the study medication but had no role in data collection or analysis.

**Partners PrEP Study Team:**

*University of Washington Coordinating Center and Central Laboratories*, Seattle, USA: Connie Celum (principal investigator, protocol co-chair), Jared M. Baeten (medical director, protocol co-chair), Deborah Donnell (protocol statistician), Robert W. Coombs, Lisa Frenkel, Craig W. Hendrix, Jairam R. Lingappa, M. Juliana McElrath.

**Study sites and site principal investigators:**
Eldoret, Kenya (Moi University, Indiana University): Kenneth H. Fife, Edwin Were; Kabwohe, Uganda (Kabwohe Clinical Research Center): Elioda Tumwesigye; Jinja, Uganda (Makerere University, University of Washington): Patrick Ndase, Elly Katabira; Kampala, Uganda (Makerere University): Elly Katabira, Allan Ronald; Kisumu, Kenya (Kenya Medical Research Institute, University of California San Francisco): Elizabeth Bukusi, Craig R. Cohen; Mbale, Uganda (The AIDS Support Organization, CDC-Uganda): Jonathan Wangisi, James D. Campbell, Jordan W. Tappero; Nairobi, Kenya (University of Nairobi, University of Washington): James Kiarie, Carey Farquhar, Grace John-Stewart; Thika, Kenya (University of Nairobi, University of Washington): Nelly R. Mugo; Tororo, Uganda (CDC-Uganda, The AIDS Support Organization): James D. Campbell, Jordan W. Tappero, Jonathan Wangisi.

Data management was provided by DF/Net Research, Inc. (Seattle, USA) and site laboratory oversight was provided by Contract Laboratory Services (CLS) of the Wits Health Consortium (University of the Witwatersrand, Johannesburg, South Africa).

Study medication was donated by Gilead Sciences.
References

1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2013; 381(9883):2083-2090.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. *New England Journal of Medicine* 2010; 363:2587-2599.
3. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet* 2016; 387(10013):53-60.
4. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. *New England Journal of Medicine* 2015; 373(23):2237-2246.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. *New England Journal of Medicine* 2012; 367:423-434.
6. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med* 2012; 367(5):399-410.
7. Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. *J Infect Dis* 2015; 211(8):1211-1218.
8. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. *Lancet Infect Dis* 2014; 14(11):1055-1064.
9. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. *AIDS* 2003; 17(13):1871-1879.
10. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. *N Engl J Med* 2011; 364(20):1943-1954.
11. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. *J Infect Dis* 2010; 202 Suppl 2:S270-277.
12. Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, et al. Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. *J Infect Dis* 2015; 212(5):754-759.
13. Baeten JM, Celum C. Antiretroviral preexposure prophylaxis for HIV prevention. *N Engl J Med* 2013; 368(1):83-84.
14. Ndase P, Celum C, Kidoguchi L, Ronald A, Fife KH, Bukusi E, et al. Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions. *PLoS One* 2015; 10(4):e0123005.
15. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. *PLoS One* 2011; 6(10):e25828.
16. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. *PLoS One* 2011; 6(1):e16475.
17. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. *Lancet* 2011; 378(9787):279-281.
18. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2011; 52 Suppl 1:S17-22.
19. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. *Sci Transl Med* 2011; 3(112):112re114.
20. Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). *AIDS Res Hum Retroviruses* 2015.
21. Suntharasamai P, Martin M, Choopanya K, Vanichseni S, Sangkum U, Tararut P, et al. Assessment of Oral Fluid HIV Test Performance in an HIV Pre-Exposure Prophylaxis Trial in Bangkok, Thailand. *PLoS One* 2015; 10(12):e0145859.
22. Curtis KA, Kennedy MS, Luckay A, Cong ME, Youngpairoj AS, Zheng Q, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. *J Acquir Immune Defic Syndr* 2011; 57(5):355-362.
23. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006; 42(5):700-708.
24. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. *PLoS Med* 2008; 5(2):e28.
25. Chirwa LI, Johnson JA, Niska RW, Segolodi TM, Henderson FL, Rose CE, et al. CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. *AIDS* 2014; 28(2):223-226.
26. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med* 2012; 367(5):411-422.
27. Grossman H, Anderson P, Grant R, Gandhi M, Mohri H, Markowitz M. Newly Acquired HIV-1 Infection with MultiDrug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP. In: R4P. Chicago; 2016.
28. Knox D, Tan D, Harrigan P, Anderson P. HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP). In: Conference on Retroviruses and Opportunistic Infections; 2016.
29. Robb ML, Eller LA, Kibuuka H, Rono K, Maganga L, Nitayaphan S, et al. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. N Engl J Med 2016; 374(22):2120-2130.
30. Rutstein SE, Pettifor AE, Phiri S, Kamanga G, Hoffman IF, Hosseinipour MC, et al. Incorporating Acute HIV Screening into Routine HIV Testing at Sexually Transmitted Infection Clinics, and HIV Testing and Counseling Centers in Lilongwe, Malawi. J Acquir Immune Defic Syndr 2016; 71(3):272-280.
31. Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, de Souza M, Luekasemsuk T, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of virus eradication 2016; 2:43-48.
32. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Annals of internal medicine 1998; 128(8):613-620.
33. Sarr AD, Eisen G, Gueye-Ndiaye A, Mullins C, Traore I, Dia MC, et al. Viral dynamics of primary HIV-1 infection in Senegal, West Africa. The Journal of infectious diseases 2005; 191(9):1460-1467.
34. Mayaphi SH, Martin DJ, Quinn TC, Laeyendecker O, Oluronju SA, Tintinger GR, et al. Detection of Acute and Early HIV-1 Infections in an HIV Hyper-Endemic Area with Limited Resources. PLoS One 2016; 11(10):e0164943.
35. Bacon O, Vittinghoff E, Cohen S, Doblecki-Lewis S, Coleman M, Buchbinder S, et al. HIV Testing in the US PrEP Demonstration Project: rEIAvs. Antigen/Antibody vs. RNA. In: Conference of Retroviral and Opportunistic Infections. Boston; 2016.
36. Delaugerre C, Charreau I, Mahjoub N, Cua E, Pasquet A, Hall N, et al. Usefulness of Rapid Tests for HIV Diagnosis in the ANRS IPERGAY Trial. In: Conference on Retroviruses and Opportunistic Infections. Boston; 2016.
37. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102(5B):117-124; discussion 125-116.
38. Ciesielski CA, Metler RP. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med 1997; 102(5B):115-116.
39. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016; 30(12):1973-1983.
40. Ananworanich J, Fletcher JLK, Pinyakorn S, van Griensven F, Vandergeeten C, Schuetz A, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013; 10:56.
Table 1: Characteristics of seroconverters, timing of site detection of infection and viral load during seroconversion (N = 138)

|                      | PrEP (N = 67) | Placebo (N = 71) |
|----------------------|---------------|------------------|
| Male                 | 27 (40%)      | 37 (52%)         |
| Plasma HIV-1 RNA viral load of partner | 4.33          | 4.43             |
| (median log_{10} copies/mL) |               |                  |
| Age (median)         | 31            | 30               |
| Infected at randomization | 9 (14%)      | 6 (8%)           |
| Time to detect seroconversion at site\(a\) | N = 58        | N = 71           |
| 0 days               | 21 (36%)      | 36 (51%)         |
| Within 100 days      | 27 (47%)      | 31 (44%)         |
| >100 days            | 10 (17%)      | 4 (6%)           |

Plasma HIV-1 RNA viral load (VL) for samples in each Fiebig stage

|                | Undetectable | Mean log_{10} VL\(b\) | Undetectable | Mean log_{10} VL |
|----------------|--------------|------------------------|--------------|-----------------|
| Overall        | 13/121 (11%) | 4/134 (3%)             |             |                 |
| Stage 2        | 2/7 (29%)    | 4.49                   | 0/10 (0%)    | 5.98            |
| Stage 3        | 0/2 (0%)     | 4.12                   | 0/1 (0%)     | 5.54            |
| Stage 4        | 1/10 (10%)   | 3.71                   | 2/11 (18%)   | 4.70            |
| Stage 5        | 3/38 (8%)    | 4.07                   | 1/43 (2%)    | 4.76            |
| Stage 6        | 7/64 (11%)   | 4.13                   | 1/69 (1%)    | 4.62            |

\(a\) 9 seroconverters in the PrEP arm and 0 on the placebo arm had no site HIV-1 test for >100 days prior to first HIV-1 infected visit. These participants are not included in the assessment of time from first HIV-1 infected sample to site detection of seroconversion.

\(b\) Samples with undetectable viral load were assigned 40 copies/mL when computing the mean.
Table 2. Time to reach Fiebig stage

| Stage  | PrEP | Placebo | PrEP: As randomized | Placebo | Relative rate to reach stage for PrEP vs. Placebo |
|--------|------|---------|---------------------|---------|-----------------------------------------------|
| Stage 2 | 5    | 3       | 0.503               | 0.288   |                                               |
| Stage 3 | 11   | 9       | 0.818               | 0.621   |                                               |
| Stage 4 | 13   | 10      | 0.781               | 0.479   |                                               |
| Stage 5 | 22   | 17      | 0.764               | 0.285   |                                               |
| Stage 6 | 60   | 49      | 0.820               | 0.490   |                                               |

PrEP: As treated

| Stage  | PrEP | Placebo | PrEP: As treated | Placebo | Relative rate to reach stage for PrEP vs. Placebo |
|--------|------|---------|------------------|---------|-----------------------------------------------|
| Stage 2 | 10   | 3       | 0.264            | 0.078   |                                               |
| Stage 3 | 16   | 9       | 0.578            | 0.255   |                                               |
| Stage 4 | 19   | 10      | 0.524            | 0.132   |                                               |
| Stage 5 | 28   | 17      | 0.599            | 0.053   |                                               |
| Stage 6 | 80   | 49      | 0.612            | 0.197   |                                               |

a Calculation of mean number of days to Stage = 1/\(a^T\) and 1/\(a^C\) respectively.

b Rates estimated by maximum likelihood assuming Uniform distribution of (unobserved) infection time and Exponential waiting time to each Fiebig stage.

c P-values based on bootstrap permutation test.
Figure 1: Time between first HIV-infected sample and site detection of seroconversion (N = 129). Time of 0 days implies site detected seroconversion occurred at the first HIV-infected visit. The PrEP arm is displayed as two groups: PrEP as-treated, participants who had tenofovir detected during the seroconversion interval; and PrEP with no tenofovir (TFV) detected. Black filled dots indicate the participants who had resistance mutations at seroconversion.
Figure 2: Fiebig stage observed in placebo, PrEP as-treated and PrEP with no tenofovir (TFV) detected groups. The tested sample for each participant is displayed on a single line. Sample times are shown at days since last HIV-1 uninfected visit, and stages for each sample displayed by color. Time interval of infection (last HIV-1 uninfected to first infected sample) is shown by dashed line. Time interval for acute/early seroconversions (first infected sample to Fiebig stage 6) is shown by a solid line.
Figure 3: Architect signal to cut-off ratio (S/CO) is plotted for each sample by stage and arm. The filled black dot indicates a sample from a participant in the PrEP arm who had detectable tenofovir during their seroconversion interval (between their last HIV-1-uninfected sample and reaching Fiebig stage 6). No differences in S/CO were observed between groups.